

# Harnessing New Treatment Modalities for Brain Metastases

Talha Adil, Zoha Khan

Azad Jammu and Kashmir Medical College, Muzaffarabad.

I'm writing to emphasize how urgently new treatment modalities for brain metastases must be developed and put into practice. This is a difficult oncology problem that still has a significant negative impact on patients and their families. We must address this pressing unmet need and enhance outcomes for patients as the prevalence of metastatic cancer to the brain rises, driven by advancements in cancer therapy and increased survival rates.<sup>1</sup>

Targeted treatments, immunotherapies, and precision radiotherapy techniques are examples of emerging therapeutics that show significant potential for improving outcomes. Clinicians can detect actionable genetic changes and customize therapy regimens to target particular molecular pathways by utilizing the potential of genomic profiling and precision medicine.<sup>2</sup>

Besides targeted medicines, immunotherapy has been a game-changer in the fight against cancer by using the body's immune system to identify and destroy tumor cells. Anti-PD-1 and anti-CTLA-4 antibodies are examples of immune checkpoint inhibitors that have demonstrated notable effectiveness in treating patients with metastatic malignancies. In patients with brain metastases, ongoing clinical trials are assessing the safety and effectiveness of immunotherapy.<sup>3,4</sup>

The management of brain metastases has also been completely transformed by developments in precision radiotherapy techniques, such as intensity-modulated radiotherapy and stereotactic radiosurgery, which allow radiation to be precisely and highly targeted to tumor lesions while sparing surrounding healthy brain tissue. In comparison to traditional whole-brain radiation therapy (WBRT),

these approaches are less intrusive and more effective while lowering the risk of neurotoxicity and cognitive loss.<sup>5</sup>

The most aggressive and fatal kind of primary brain cancer, glioblastoma multiforme (GBM), has been shown in preclinical animals to be amenable to hydrogel-based drug delivery methods. By encasing chemotherapeutic medications, researchers were able to achieve sustained release kinetics, longer drug retention at the tumor location, and increased therapeutic benefits. Medical professionals can also surmount the blood-brain barrier, and encourage tissue regrowth, revolutionizing the field of brain tumor therapy.<sup>6</sup>

In conclusion, this rapidly developing discipline of treating brain metastases offers patients fresh hope by representing a frontier of potential and innovation in oncology improving their quality of life. It is our joint duty as researchers, physicians, and legislators to give priority to and encourage the development of novel brain metastasis treatment approaches in order to guarantee that every patient receives the finest care available and the chance for a better future. Thank you for considering my thoughts on this matter.

<i>Treatment Modality</i>	<i>Mode of Action in Treating Brain Tumor</i>
Immunotherapy of brain metastases.	Targeting tumor-brain microenvironment interactions and emerging treatment modalities.
Brain radiotherapy with immune checkpoint blockade.	Utilizing CTLA-4-directed blockade with or without trastuzumab in breast cancer brain metastases.
Immune-mediated therapy in NSCLC patients.	Understanding and dissecting outcomes from immune checkpoint blockade in the tumors.
Immune-checkpoint inhibition and targeted therapy in melanoma brain metastases.	Providing insights into the inhibition of biological factors leading to melanoma and its metastases in brain.

#### Abbreviations

PD-1 – Programmed Cell Death Protein 1, CTLA-4 – Cytotoxic T-Lymphocyte associated Protein-4, GBM – Glioblastoma Multiforme

**Conflict of Interest:** None declared.

#### Corresponding Author:

**Talha Adil**

Azad Jammu and Kashmir Medical College  
Muzaffarabad.

Email: [talhaadil2000@gmail.com](mailto:talhaadil2000@gmail.com)

**Received:** 17 July 2024, **Accepted:** 02 March 2026

**Published:** 28 April 2026

Copyright © 2026 The Author(s). This is an Open Access article under the CC BY-NC 4.0 license.

## References

1. Zhou D, Gong Z, Wu D, Ma C, Hou L, Niu X, et al. Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities. *J Hematol Oncol* 2023; 16(1): 121.
  2. Di Giacomo AM, Valente M, Cerase A, Lofiego MF, Piazzini F, Calabro L. et al. Immunotherapy of brain metastases: breaking a “dogma.” *J ExpClin Cancer Res* 2019; 38(1): 419.
  3. Page DB, Beal K, Linch SN, Spinelly KJ, Rodine M, Halpenny D, et al. Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases. *NPJ Breast Cancer* 2022; 8(1): 50.
  4. Vilariño N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. *Cancer Treat Rev* 2020; 89: 102067.
  5. Hilbers ML, Dimitriou F, Lau P, Bhave P, McAurthur GA, Zimmer L, et al. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. *Eur J Cancer* 2021;156:149-63.
  6. Berger LA, Riesenber H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives. *Lung Cancer* 2013; 80(3): 242-8.
-